These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3692120)

  • 21. An update on disordered iron metabolism and iron overload.
    Ward R
    Hematology; 2010 Oct; 15(5):311-7. PubMed ID: 20863426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of long term iron chelation treatment with deferoxamine.
    Davis BA; Porter JB
    Adv Exp Med Biol; 2002; 509():91-125. PubMed ID: 12572991
    [No Abstract]   [Full Text] [Related]  

  • 23. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ
    Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract]   [Full Text] [Related]  

  • 24. Thalassemia in Britain and Australia.
    Modell B; Matthews R
    Birth Defects Orig Artic Ser; 1976; 12(8):13-29. PubMed ID: 795477
    [No Abstract]   [Full Text] [Related]  

  • 25. Combining two orally active iron chelators for thalassemia.
    Berdoukas V; Carson S; Nord A; Dongelyan A; Gavin S; Hofstra TC; Wood JC; Coates T
    Ann Hematol; 2010 Nov; 89(11):1177-8. PubMed ID: 20217085
    [No Abstract]   [Full Text] [Related]  

  • 26. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical Management of Patients With Thalassemia Syndromes.
    Martin M; Haines D
    Clin J Oncol Nurs; 2016 Jun; 20(3):310-7. PubMed ID: 27206298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 32. Compliance with therapy in Cooley's anaemia.
    Vullo C; Di Palma A
    Prog Clin Biol Res; 1989; 309():43-9. PubMed ID: 2780749
    [No Abstract]   [Full Text] [Related]  

  • 33. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation.
    Hershko C; Link G; Pinson A
    Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
    [No Abstract]   [Full Text] [Related]  

  • 35. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
    J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
    Pippard MJ
    Acta Haematol; 1987; 78(2-3):206-11. PubMed ID: 3120473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transfusional iron overload.
    Marcus RE; Huehns ER
    Clin Lab Haematol; 1985; 7(3):195-212. PubMed ID: 3907937
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New therapeutic trends in thalassemia: oral chelating agents].
    Carnelli V; Terzoli S; Fossati G; Careddu G; Perri M; Pedrotti L; Mirra N
    Pediatr Med Chir; 1992; 14(3):273-5. PubMed ID: 1528794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.